LEVEL 4 L01XX27

Δραστικές

ARSENIC

Φάρμακα

  • DRUGBANK - Arsenic trioxide
  • indication:

    For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression

  • pharmacology:

  • mechanism:

    The mechanism of action of Arsenic Trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells <i>in vitro</i>. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR-alpha. It is suspected that arsenic trioxide induces cancer cells to undergo apoptosis.

  • toxicity:

    Symptoms of overdose include convulsions, muscle weakness and confusion.

  • absorprion:

  • halflife:

  • roouteelimination:

    Trivalent arsenic is mostly methylated in humans and excreted in urine.

  • volumedistribution:

  • clearance: